Literature DB >> 8220907

Vascular actions of purines in the foetal circulation of the human placenta.

M A Read1, A L Boura, W A Walters.   

Abstract

1. The vasoactive effects of adenosine triphosphate (ATP), adenosine and other purines in the foetal circulation of the human placenta were examined. Single lobules of the placenta were bilaterally perfused in vitro with Krebs buffer (maternal and foetal sides 5 ml min-1 each, 95% O2:5% CO2, 37 degrees C). Changes in foetal vascular tone were assessed by recording perfusion pressure during constant infusion of each purine. To allow recording of the vasodilator effects, submaximal vasoconstriction was induced by concomitant infusion of prostaglandin F2 alpha (0.7-2.0 mumol l-1). 2. ATP (1.0-100 mumol l-1) usually caused concentration-dependent reductions in perfusion pressure. However, biphasic with initial transient increases, or only increases in pressure were sometimes observed. Falls in pressure caused by ATP were significantly reduced by addition to the perfusate of NG-nitro-L-arginine (L-NOARG) (100 mumol l-1) but not NG-nitro-D-arginine (D-NOARG) (100 mumol l-1). They were not influenced by addition of indomethacin (10 mumol l-1) or L-arginine (100 mumol l-1). 3. Adenosine (0.01-1.0 mmol l-1) consistently caused concentration-dependent reductions in perfusion pressure, this effect not being influenced by indomethacin. L-NOARG, but not D-NOARG, reduced the potency of adenosine approximately three fold. L-Arginine, but not D-arginine enhanced its potency by a similar amount. 4. 2-Methylthio-ATP, a selective P2 gamma agonist was approximately 50 times more potent than ATP as a vasodilator agent, always causing decreases in perfusion pressure. 5. Beta-gamma-Methylene ATP, a selective P20 agonist, was approximately 100 times more potent than ATP as a vasoconstrictor, but only caused transient increases in perfusion pressure.6. The rank order of vasodilator potencies of a selection of adenosine receptor agonists was, 2-chloroadenosine>>5-(N-cyclopropyl)-carboxamidoadenosine, >5-N-ethylcarboxamidoadenosine, >2-chloro-N6-cyclopentyladenosine, >CGS-21680 > N6-cyclohexyladenosine = adenosine. Vasodilatation due to adenosine was inhibited by the PI-A2 receptor antagonist 3,7-dimethyl-l-propargylxanthine(DMPX).7. These results suggest that ATP may cause an endothelium-dependent vasodilatation in the foetal vessels of the human placenta via activation of a P2y receptor linked to the formation of nitric oxide(NO). Vasodilatation caused by ATP may mask an accompanying vasoconstrictor effect mediated, via a P2X receptor, in the villous vascular smooth muscle. Adenosine acting on P1-A2 receptors, which are also present in the foetal vasculature, may require synergistic interaction with NO to achieve a maximal vasodilator response.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8220907      PMCID: PMC2175974          DOI: 10.1111/j.1476-5381.1993.tb13832.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

1.  A novel receptor-operated Ca2+-permeable channel activated by ATP in smooth muscle.

Authors:  C D Benham; R W Tsien
Journal:  Nature       Date:  1987 Jul 16-22       Impact factor: 49.962

2.  Role of endothelium-derived nitric oxide in maintenance of low fetal vascular resistance in placenta.

Authors:  N M Gude; R G King; S P Brennecke
Journal:  Lancet       Date:  1990 Dec 22-29       Impact factor: 79.321

3.  Characteristics of the P2 purinoceptor that mediates prostacyclin production by pig aortic endothelial cells.

Authors:  L Needham; N J Cusack; J D Pearson; J L Gordon
Journal:  Eur J Pharmacol       Date:  1987-02-10       Impact factor: 4.432

4.  Characterization of P2X- and P2Y-purinoceptors in the rabbit hepatic arterial vasculature.

Authors:  V Ralevic; R T Mathie; B Alexander; G Burnstock
Journal:  Br J Pharmacol       Date:  1991-05       Impact factor: 8.739

5.  2-Chloro-N6-cyclopentyladenosine: a highly selective agonist at A1 adenosine receptors.

Authors:  M J Lohse; K N Klotz; U Schwabe; G Cristalli; S Vittori; M Grifantini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-06       Impact factor: 3.000

6.  An in vitro analysis of purine-mediated renal vasoconstriction in rat isolated kidney.

Authors:  T P Kenakin; N B Pike
Journal:  Br J Pharmacol       Date:  1987-02       Impact factor: 8.739

7.  Ligand selectivity of dog coronary adenosine receptor resembles that of adenylate cyclase stimulatory (Ra) receptors.

Authors:  S Kusachi; R D Thompson; R A Olsson
Journal:  J Pharmacol Exp Ther       Date:  1983-11       Impact factor: 4.030

8.  Different P2-purinergic receptor subtypes of endothelium and smooth muscle in canine blood vessels.

Authors:  D A Houston; G Burnstock; P M Vanhoutte
Journal:  J Pharmacol Exp Ther       Date:  1987-05       Impact factor: 4.030

9.  L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation.

Authors:  R M Palmer; D D Rees; D S Ashton; S Moncada
Journal:  Biochem Biophys Res Commun       Date:  1988-06-30       Impact factor: 3.575

10.  CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity.

Authors:  A J Hutchison; R L Webb; H H Oei; G R Ghai; M B Zimmerman; M Williams
Journal:  J Pharmacol Exp Ther       Date:  1989-10       Impact factor: 4.030

View more
  12 in total

1.  Calcitonin gene-related peptide contributes to the umbilical haemodynamic defence response to acute hypoxaemia.

Authors:  A S Thakor; D A Giussani
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

2.  Maternal hypoxia and caffeine exposure depress fetal cardiovascular function during primary organogenesis.

Authors:  Nobuo Momoi; Joseph P Tinney; Bradley B Keller; Kimimasa Tobita
Journal:  J Obstet Gynaecol Res       Date:  2012-05-21       Impact factor: 1.730

Review 3.  Purinergic signalling in the reproductive system in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-11-23       Impact factor: 3.765

Review 4.  Adenosine A₂a receptors and O₂ sensing in development.

Authors:  Brian J Koos
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-06-15       Impact factor: 3.619

5.  Insulin requires A1 adenosine receptors expression to reverse gestational diabetes-increased L-arginine transport in human umbilical vein endothelium.

Authors:  Enrique Guzmán-Gutiérrez; Axel Armella; Fernando Toledo; Fabián Pardo; Andrea Leiva; Luis Sobrevia
Journal:  Purinergic Signal       Date:  2015-12-28       Impact factor: 3.765

6.  Activation of A2-purinoceptors by adenosine stimulates L-arginine transport (system y+) and nitric oxide synthesis in human fetal endothelial cells.

Authors:  L Sobrevia; D L Yudilevich; G E Mann
Journal:  J Physiol       Date:  1997-02-15       Impact factor: 5.182

7.  High plasma adenosine levels in overweight/obese pregnant women.

Authors:  Priscila Badillo; Paola Salgado; Patricia Bravo; Katherine Guevara; Jesenia Acurio; Maria Angelica Gonzalez; Carlos Oyarzun; Rody San Martin; Carlos Escudero
Journal:  Purinergic Signal       Date:  2017-07-18       Impact factor: 3.765

8.  Adenosine mediates metabolic and cardiovascular responses to hypoxia in fetal sheep.

Authors:  B J Koos; A Chau; D Ogunyemi
Journal:  J Physiol       Date:  1995-11-01       Impact factor: 5.182

9.  Enhanced nitric oxide activity offsets peripheral vasoconstriction during acute hypoxaemia via chemoreflex and adrenomedullary actions in the sheep fetus.

Authors:  Suzanne Morrison; David S Gardner; Andrew J W Fletcher; Malcolm R Bloomfield; Dino A Giussani
Journal:  J Physiol       Date:  2003-01-10       Impact factor: 5.182

10.  Insulin-increased L-arginine transport requires A(2A) adenosine receptors activation in human umbilical vein endothelium.

Authors:  Enrique Guzmán-Gutiérrez; Francisco Westermeier; Carlos Salomón; Marcelo González; Fabián Pardo; Andrea Leiva; Luis Sobrevia
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.